Glenmark USA to Launch Sodium Phosphates Injection USP in April 2026

Glenmark Pharmaceuticals' US subsidiary plans to launch Sodium Phosphates Injection USP in April 2026, offering single-dose vials in three concentrations. The product is bioequivalent and therapeutically equivalent to Hospira's reference drug, with FDA safety and effectiveness reliance. The market for these injections recorded approximately $66.8 million in annual sales by December 2025. Glenmark aims to provide quality, affordable alternatives and expand its institutional product portfolio.